BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stark T, Di Bartolomeo M, Di Marco R, Drazanova E, Platania CBM, Iannotti FA, Ruda-Kucerova J, D'Addario C, Kratka L, Pekarik V, Piscitelli F, Babinska Z, Fedotova J, Giurdanella G, Salomone S, Sulcova A, Bucolo C, Wotjak CT, Starcuk Z Jr, Drago F, Mechoulam R, Di Marzo V, Micale V. Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochem Pharmacol 2020;177:114004. [PMID: 32360362 DOI: 10.1016/j.bcp.2020.114004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Palumbo JM, Thomas BF, Budimirovic D, Siegel S, Tassone F, Hagerman R, Faulk C, O'Quinn S, Sebree T. Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment. J Neurodev Disord 2023;15:1. [PMID: 36624400 DOI: 10.1186/s11689-023-09475-z] [Reference Citation Analysis]
2 Micale V, Di Bartolomeo M, Di Martino S, Stark T, Dell'Osso B, Drago F, D'Addario C. Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets. Pharmacol Ther 2023;241:108279. [PMID: 36103902 DOI: 10.1016/j.pharmthera.2022.108279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Pavlova I, Drazanova E, Kratka L, Amchova P, Macicek O, Starcukova J, Starcuk Z, Ruda-kucerova J. Laterality in functional and metabolic state of the bulbectomised rat brain detected by ASL and 1 H MRS: a pilot study. The World Journal of Biological Psychiatry. [DOI: 10.1080/15622975.2022.2124450] [Reference Citation Analysis]
4 Micallef J, Batisse A, Revol B. Pharmacologie du cannabidiol : points de vigilance, conséquences et risques chez l’homme. Therapies 2022;77:585-590. [DOI: 10.1016/j.therap.2022.02.001] [Reference Citation Analysis]
5 Pedrazzi JFC, Ferreira FR, Silva-Amaral D, Lima DA, Hallak JEC, Zuardi AW, Del-Bel EA, Guimarães FS, Costa KCM, Campos AC, Crippa ACS, Crippa JAS. Cannabidiol for the treatment of autism spectrum disorder: hope or hype? Psychopharmacology (Berl) 2022. [PMID: 35904579 DOI: 10.1007/s00213-022-06196-4] [Reference Citation Analysis]
6 Smith RC, Sershen H, Janowsky DS, Lajtha A, Grieco M, Gangoiti JA, Gertsman I, Johnson WS, Marcotte TD, Davis JM. Changes in Expression of DNA-Methyltransferase and Cannabinoid Receptor mRNAs in Blood Lymphocytes After Acute Cannabis Smoking. Front Psychiatry 2022;13:887700. [DOI: 10.3389/fpsyt.2022.887700] [Reference Citation Analysis]
7 Kibret BG, Ishiguro H, Horiuchi Y, Onaivi ES. New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders. Int J Mol Sci 2022;23:975. [PMID: 35055161 DOI: 10.3390/ijms23020975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
8 Stark T, Iannotti FA, Di Martino S, Di Bartolomeo M, Ruda-kucerova J, Piscitelli F, Wotjak CT, D’addario C, Drago F, Di Marzo V, Micale V. Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia. Biomolecules 2022;12:108. [DOI: 10.3390/biom12010108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Shen B, Zhang D, Zeng X, Guan L, Yang G, Liu L, Huang J, Li Y, Hong S, Li L. Cannabidiol inhibits methamphetamine-induced dopamine release via modulation of the DRD1-MeCP2-BDNF-TrkB signaling pathway. Psychopharmacology (Berl) 2022. [PMID: 34997862 DOI: 10.1007/s00213-021-06051-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Henson JD, Vitetta L, Quezada M, Hall S. Enhancing Endocannabinoid Control of Stress with Cannabidiol. J Clin Med 2021;10:5852. [PMID: 34945148 DOI: 10.3390/jcm10245852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 de Melo Reis RA, Isaac AR, Freitas HR, de Almeida MM, Schuck PF, Ferreira GC, Andrade-da-Costa BLDS, Trevenzoli IH. Quality of Life and a Surveillant Endocannabinoid System. Front Neurosci 2021;15:747229. [PMID: 34776851 DOI: 10.3389/fnins.2021.747229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
12 Stark T, Di Martino S, Drago F, Wotjak CT, Micale V. Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. Pharmacol Res 2021;174:105938. [PMID: 34655773 DOI: 10.1016/j.phrs.2021.105938] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
13 Gesualdo C, Balta C, Platania CBM, Trotta MC, Herman H, Gharbia S, Rosu M, Petrillo F, Giunta S, Della Corte A, Grieco P, Bellavita R, Simonelli F, D'Amico M, Hermenean A, Rossi S, Bucolo C. Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study. Front Pharmacol 2021;12:718902. [PMID: 34603029 DOI: 10.3389/fphar.2021.718902] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 de Almeida DL, Devi LA. Diversity of molecular targets and signaling pathways for CBD. Pharmacol Res Perspect 2020;8:e00682. [PMID: 33169541 DOI: 10.1002/prp2.682] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 18.5] [Reference Citation Analysis]
15 Jiang H, Li H, Cao Y, Zhang R, Zhou L, Zhou Y, Zeng X, Wu J, Wu D, Wu D, Guo X, Li X, Wu H, Li P. Effects of cannabinoid (CBD) on blood brain barrier permeability after brain injury in rats. Brain Res 2021;1768:147586. [PMID: 34289379 DOI: 10.1016/j.brainres.2021.147586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
16 Kwan Cheung KA, Mitchell MD, Heussler HS. Cannabidiol and Neurodevelopmental Disorders in Children. Front Psychiatry 2021;12:643442. [PMID: 34093265 DOI: 10.3389/fpsyt.2021.643442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Navarrete F, García-Gutiérrez MS, Gasparyan A, Austrich-Olivares A, Manzanares J. Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders. Front Pharmacol 2021;12:626010. [PMID: 34093179 DOI: 10.3389/fphar.2021.626010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
18 Hassanlou AA, Jamali S, RayatSanati K, Mousavi Z, Haghparast A. Cannabidiol modulates the METH-induced conditioned place preference through D2-like dopamine receptors in the hippocampal CA1 region. Brain Res Bull 2021;172:43-51. [PMID: 33862125 DOI: 10.1016/j.brainresbull.2021.04.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
19 Graczyk M, Łukowicz M, Dzierzanowski T. Prospects for the Use of Cannabinoids in Psychiatric Disorders. Front Psychiatry 2021;12:620073. [PMID: 33776815 DOI: 10.3389/fpsyt.2021.620073] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
20 Loss CM, Teodoro L, Rodrigues GD, Moreira LR, Peres FF, Zuardi AW, Crippa JA, Hallak JEC, Abílio VC. Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? Front Pharmacol 2020;11:635763. [PMID: 33613289 DOI: 10.3389/fphar.2020.635763] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
21 Kiss B, Laszlovszky I, Krámos B, Visegrády A, Bobok A, Lévay G, Lendvai B, Román V. Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders. Biomolecules 2021;11:104. [PMID: 33466844 DOI: 10.3390/biom11010104] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
22 Di Bartolomeo M, Stark T, Maurel OM, Iannotti FA, Kuchar M, Ruda-Kucerova J, Piscitelli F, Laudani S, Pekarik V, Salomone S, Arosio B, Mechoulam R, Maccarrone M, Drago F, Wotjak CT, Di Marzo V, Vismara M, Dell'Osso B, D'Addario C, Micale V. Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats. Pharmacol Res 2021;164:105357. [PMID: 33285233 DOI: 10.1016/j.phrs.2020.105357] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
23 Wanner NM, Colwell M, Drown C, Faulk C. Subacute cannabidiol alters genome-wide DNA methylation in adult mouse hippocampus. Environ Mol Mutagen 2020;61:890-900. [PMID: 32579259 DOI: 10.1002/em.22396] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]